2. Search Result
Search Result
Results for "

mPTP Inhibitor

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

1

Peptides

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-119909
    GNX-865

    		Mitochondrial Metabolism Cardiovascular Disease
    GNX-865 is a mitochondrial permeability transition pore (mPTP) inhibitor that protects against ischemia-reperfusion injury in vivo .
    GNX-865
  • HY-100852
    ER-000444793
    4 Publications Verification

    		 Mitochondrial Metabolism Cancer
    ER-000444793 is a potent inhibitor of mitochondrial permeability transition pore (mPTP) opening. ER-000444793 inhibits mPTP with an IC50 of 2.8 μM.
    ER-000444793
  • HY-112715
    ATP synthase inhibitor 1

    		ATP Synthase Cardiovascular Disease
    ATP synthase inhibitor 1 is a potent inhibitor of c subunit of the F1/FO-ATP synthase complex, inhibits mitochondrial permeability transition pore (mPTP) opening, does not affect ATP levels .
    ATP synthase inhibitor 1
  • HY-117173
    (Rac)-Rasagiline

    AGN1135; (Rac)-TVP1012

    		 Monoamine Oxidase Neurological Disease
    (Rac)-Rasagiline (AGN1135) is the racemate of Rasagiline. (Rac)-Rasagiline is a selective type B MAO (MAO-B) inhibitor. (Rac)-Rasagiline can be used for Parkinson's disease research. (Rac)-Rasagiline protects against MPTP (HY-15608)-induced toxicity .
    (Rac)-Rasagiline
  • HY-157088
    C105SR

    		Caspase Apoptosis Cyclophilin Others
    C105SR is a cyclophilin D (CypD) inhibitor targeting to peptidyl-prolylcis-trans isomerase (PPIase). C105SR inhibits mitochondrial permeability transition opening (mPTP) with an IC 50 of 5 nM. C105SR inhibits hypoxia and reoxygenation inudced hepatocyte apoptosis and increases the level of calcium retention capacity (CRC). C105SR exhibits hepaprotective effect in ischaemia-reperfusion injury (IRI) mouse model .
    C105SR
  • HY-172959
    mPTP-IN-1

    		Mitochondrial Metabolism Cardiovascular Disease
    mPTP-IN-1 (Compound 14e) is a mitochondrial permeability transition pore (mPTP) inhibitor. mPTP-IN-1 blocks calcium-induced mPTP opening by targeting the C subunit of ATP synthase. mPTP-IN-1 can be used to study myocardial ischemia/reperfusion injury (IRI) .
    mPTP-IN-1
  • HY-116550
    Piroheptine hydrochloride

    		Dopamine Transporter Neurological Disease
    Piroheptine hydrochloride is an anticholinergic agent to inhibit dopamine uptake. Piroheptine hydrochloride prevents loss of striatal dopamine induced by MPTP (HY-15608). Piroheptine hydrochloride can be used for research in Parkinson .
    Piroheptine hydrochloride
  • HY-P6437
    Drp1 peptide inhibitor P110

    		Dynamin Cardiovascular Disease Neurological Disease
    Drp1 peptide inhibitor P110 (Compound P110) is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 can inhibit the activation of Drp1, prevent MPTP-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .
    Drp1 peptide inhibitor P110
  • HY-136804
    CypD-IN-29

    		Cyclophilin Neurological Disease
    CypD-IN-29 (compound 29) is an inhibitor of the Alzheimer's disease target CypD (KD=88.2 nM). CypD is a mitochondrial-specific cyclophilin that can bind to β-amyloid protein in brain mitochondria and promote the formation of mitochondrial permeability transition pore (mPTP).
    CypD-IN-29
  • HY-168169
    hMAO-B-IN-10

    		Monoamine Oxidase Neurological Disease
    hMAO-B-IN-10 (compound 7) is an inhibitor of MAO-A/B with IC50 of 424.1 nM and 177.9 nM, respectively. hMAO-B-IN-10 exerts a certain neuroprotective effect in MPTP (HY-15608)-induced mouse PD model. .
    hMAO-B-IN-10
  • HY-162573
    Monoamine Oxidase B inhibitor 5

    		Monoamine Oxidase Neurological Disease
    Monoamine Oxidase B inhibitor 5 (Compound 16d) is a selective and reversible inhibitor for monoamine oxidase B (hMAO-B) with an IC50 of 67.3 nM and a Ki of 82.5 nM. Monoamine Oxidase B inhibitor 5 exhibits good pharmacokinetic characters and weak toxicity in rats model. Monoamine Oxidase B inhibitor 5 alleviates MPTP-induced (HY-15608) motor impairment in Parkinson’s mouse model. Monoamine Oxidase B inhibitor 5 is blood-brain barrier (BBB) penetrate .
    Monoamine Oxidase B inhibitor 5
  • HY-162760
    COMT-IN-1

    		COMT Monoamine Oxidase Neurological Disease
    COMT-IN-1 (compound C12), a nitrophenolic analogue, is an orally active dopamine metabolic enzyme catechol-O-methyltransferase (COMT) inhibitor with IC50s of 0.37 μM, 95.58 μM and 58.82 μM for COMT, MAO-A and MAO-B, respectively. COMT-IN-1 exhibits chelation with a variety of metal ions. COMT-IN-1 exhibits good BBB permeability. COMT-IN-1 improves dopamine levels and ameliorates MPTP (HY-15608)-induced Parkinson's disease (PD) symptoms in mice .
    COMT-IN-1
  • HY-158732
    MAO-B-IN-33

    		Monoamine Oxidase Inflammation/Immunology
    MAO-B-IN-33 (compound C3) is a potent, reversible and selective monoamine oxidase-B (MAO-B) inhibitor with an IC50 of 0.021 μM and 26.805 μM for MAO-B and MAO-A, respectively. The selectivity of MAO-B-IN-33 is attributed to the steric clash arising from the residue differences between Phe208 (MAO-A) and Ile199 (MAO-B). MAO-B-IN-33 inhibits cerebral MAO-B activity and alleviates MPTP (HY-15608)-induced dopaminergic neuronal loss in the mouse. MAO-B-IN-33 has the potential for Parkinson's disease research .
    MAO-B-IN-33
  • HY-15763
    Erastin
    565+ Cited Publications

    		 VDAC Ferroptosis Disulfidptosis Cancer
    Erastin is a ferroptosis inducer. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity. Furthermore, Erastin can block the uptake of cystine mediated by SLC7A11 and also spares UMRC6-EV and -C91A cells from disulfidptosis under glucose starvation .
    Erastin
  • HY-131036
    MAO-IN-M30 dihydrochloride

    		Monoamine Oxidase Neurological Disease
    MAO-IN-M30 dihydrochloride is an orally active, brain-permeable, and brain selective irreversible MAO-A (IC50=37 nM) and MAO-B (IC50=57 nM) inhibitor. MAO-IN-M30 dihydrochloride is a potent iron chelator and radical scavenger. MAO-IN-M30 dihydrochloride has a neuroprotective effect against Dexamethasone-induced brain cell apoptosis. MAO-IN-M30 dihydrochloride also exhibits neurorestorative activity in post MPTP and lactacystin models of Parkinson's disease . MAO-IN-M30 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MAO-IN-M30 dihydrochloride
  • HY-W587743
    N1-Acetyl-5-methoxykynuramine hydrochloride

    AMK hydrochloride

    		 Prostaglandin Receptor PGE synthase COX Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease
    N1-Acetyl-5-methoxykynuramine (AMK) hydrochloride is an active metabolite of the neurohormone melatonin (HY-B0075). N1-Acetyl-5-methoxykynuramine hydrochloride (200 µM) effectively scavenges singlet oxygen (ROS).1 It also inhibits the production of prostaglandin E2 (PGE2) and prostaglandin D2 (PGD2) induced by epinephrine and arachidonic acid in a concentration- and time-dependent manner, and suppresses the increase in COX-2 levels induced by LPS (HY-D1056) in RAW 264.7 macrophages at a concentration of 500 µM. In a mouse model of Parkinson's disease induced by MPTP (HY-15608), N1-Acetyl-5-methoxykynuramine hydrochloride (20 mg/kg) reduces the increase in lipid peroxidation in the cytosol and mitochondria of the substantia nigra and striatum. N1-Acetyl-5-methoxykynuramine hydrochloride can be used in research on metabolic and neurological diseases
    N1-Acetyl-5-methoxykynuramine hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: